Paladin Labs startet durch!

solide Partnerschaften und Umsätze, echt stark. unbedingt anschauen!!!

Technologie einverleibt, Aktienrückkaufprogramm, einfach der Hammer!

Hier kann man glaube ich gar nicht verlieren. das ist Morphosys verdächtig? Sichere Gewinne und Milliarden potential?


Paladin Labs is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market   Strong revenue growth •   5 year CAGR revenue growth of 21%   Healthy, robust business •   Generated $19.9 million of EBITDA in 2007 or $1.30 per share   Rich, near-term pipeline for growth •   1 product awaiting regulatory approval •   8 products in phase I, II and III

von der Homepage!! www.paladin-labs.com/forinvestors/presentations.html

Ich wünsche viel Freude mit Diesem Investment.  

gruss macos

Strong Balance Sheet to Fund Future Growth•
•Current Share Price • $10.40  
•Shares Outstanding • 14.8M    
•2008 Revenue Guidance •$73M to $75M  
•Cash and Short Term Investments 2008 •  $36.5 M
•EBITDA 1st 6 months 2008 •$12.4 M
•Revenue 1st 6 months 2008 $37.5 M

KGV von ca 5 ?

sehr starker Wachstumswert!

Sancuso® is a transdermal patch that delivers granisetron, an established 5HT3 receptor antagonist, and is indicated for the prevention of nausea and vomiting in patients undergoing chemotherapy for up to 5 consecutive days. Sancuso® has the advantage of offering this protection through a single transdermal patch application, eradicating the need for repeated daily injections or having to swallow multiple pills on a repeated daily basis. Sancuso® is currently approved in the United States and was named by Time magazine as one of the top medical breakthroughs in 2008. Based on IMS Canada data, Paladin estimates the total chemotherapy induced nausea and vomiting market at approximately $45 million. The largest molecule in this category is ondansetron with approximately $19 million in sales.

"It is our intention to submit these two innovative products for Canadian regulatory approval in mid-2009. We expect Abstral® and Sancuso® to fulfill an unmet need for cancer patients in Canada," said Jonathan Ross Goodman, President and Chief Executive Officer of Paladin Labs Inc. "These products complement our dynamic and growing promoted pain portfolio, which already includes TriduralTM, Metadol® and Pennsaid®, and provides us an additional pillar upon which to build out a supportive care oncology franchise."

"Our strategy is to ensure that we capitalize on the strength of our high value products through out-licensing agreements in territories that are non-core for ProStrakan. In Paladin, we have a partner with demonstrable sales and marketing expertise, particularly in the area of cancer pain, and a very significant presence in the Canadian pharmaceuticals market" said Dr. Wilson Totten, Chief Executive Officer, ProStrakan Group plc.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. For more information, please visit the Company's web site at www.paladinlabs.com.

About ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. ProStrakan's head office is situated in Galashiels in Scotland. The company's development capabilities are centred on Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries. For more information, please visit the Company's web site at
www.prostrakan.com

Forward-Looking Statements

This news release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Paladin Labs Inc. (the "Company") considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2007. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com


FOR FURTHER INFORMATION PLEASE CONTACT:

Paladin Labs Inc.
Samira Sakhia
Chief Financial Officer
514-340-5067
514-344-4675 (FAX)
info@paladin-labs.com

or

ProStrakan Group plc
Callum Spreng
Corporate Communications
44 1896 664103





gruss macos

Paladin to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
Tuesday February 10, 2009, 8:00 am EST
Yahoo! Buzz Print MONTREAL, QUEBEC--(Marketwire - Feb. 10, 2009) - Paladin Labs Inc. (TSX:PLB - News), a leading Canadian specialty pharmaceutical company, today announced that Jonathan Ross Goodman, President and CEO, will present a corporate update at the Roth Capital Partners 21st Annual OC Growth Stock Conference on February 16, 2009 at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time) at The Ritz Carlton Laguna Niguel in Dana Point, California. A copy of the presentation will be available at www.paladinlabs.com.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. For more information, please visit the Company's web site at www.paladinlabs.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended December 31, 2007. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Companies' ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at www.sedar.com.

Contact:
Samira Sakhia
Paladin Labs Inc.
Chief Financial Officer
514-340-5067

läuft weiter, kein Wunder bei der Unterbewertung!

"We have just closed our 13th consecutive year of record revenues and have built a diversified specialty pharma business that is dynamic, proven and high performing in all respects. Indeed, our key promoted products revenues increased over 40% in 2008 and our financial investment in new products was the largest in our corporate history. This expansion of our marketed portfolio and pipeline has been accomplished with exciting, medically important therapeutics that have the potential to drive strong, organic growth for the foreseeable future. We expect Paladin to breakthrough a significant Canadian business threshold in 2009 and become a $100 million company," said Jonathan Ross Goodman, President and CEO of Paladin Labs.

Financial Results

Revenues for the fourth quarter of 2008 increased 30% to a record $23.1 million compared to $17.7 million in the fourth quarter of 2007. Revenues from the Company's key promoted brands including: Tridural(TM), Twinject®, Plan B®, Pennsaid®, Metadol®, Seasonale(TM), Testim® and Trelstar® increased by 22% in the fourth quarter of 2008 compared to the same period a year ago. For the year ended December 31, 2008, revenues increased 31% to a record $82.7 million compared to $62.9 million in 2007.

EBITDA(1) for the fourth quarter in 2008 increased to $7.4 million compared to EBITDA(1) of $4.9 million in the fourth quarter 2007. For the year ended December 31, 2008, EBITDA(1) increased to a record $29.0 million compared to $19.9 million in 2007.

Net income before extraordinary gain for the fourth quarter 2008 was $2.0 million or $0.14 per fully diluted share compared to the same period in 2007 of $1.0 million or $0.07 per diluted share. Net income for the fourth quarter was $6.1 million or $0.41 per fully diluted share compared to net income of $1.0 million or $0.07 per fully diluted share in 2007. Net income before extraordinary gain for the year ended December 31, 2008 was $9.7 million or $0.65 per fully diluted share compared to $4.2 million or $0.27 per fully diluted share in 2007. Net income for the year ended December 31, 2008 was a record $13.8 million or $0.92 per fully diluted share, compared to net income of $9.0 million or $0.59 per fully diluted share in 2007.

Selling and marketing expense for the fourth quarter of 2008 decreased to $5.5 million compared to $7.4 million in the fourth quarter of 2007. Selling and marketing expense for the year ended December 31, 2008 remained constant at $22 million compared to 2007.

Amortization expense for the fourth quarter 2008 increased slightly to $3.4 million from $3.2 million in the corresponding period a year ago. For the twelve-month period ended December 31, 2008, amortization expense increased slightly to $12.6 million from $12.5 million in 2007.

As at December 31 2008, Paladin's cash, cash equivalents and investments in marketable securities totaled $21.3 million. From this strong cash position, Paladin continues to pursue product acquisition opportunities.

Financial Outlook

In 2009, Paladin expects to generate at least $100 million in revenue. This forecast excludes the impact of acquisitions that may be made by the Company between now and the end of 2009.

Conference Call Notice

Paladin will host a conference call to discuss its fourth quarter results today at 10:00 a.m. EST. The dial-in number for the conference call is 1-800-732-0232 or 416-644-3419. The call will be audio-cast live and archived for 31 days at www.paladinlabs.com.

(1) EBITDA (earnings before interest, taxes, depreciation and amortization) does not have any standardized meaning under Canadian Generally Accepted Accounting Principles ("GAAP") and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest expense, taxes, amortization, and unusual items; such as write-downs and gains (losses) on intellectual property and investments. EBITDA is calculated and presented consistently from period to period and agrees, on a consolidated basis, with the amount disclosed as "Earnings before under noted items" on the consolidated statement of income. The Company believes EBITDA to be an important measurement that allows it to assess the operating performance of its ongoing business on a consistent basis without the impact of amortization expenses. The Company excludes amortization expenses because their level depends substantially on non-operating factors such as the historical cost of intangible and capital assets. The Company's method for calculating EBITDA may differ from that used by other issuers and, accordingly, this measure may not be comparable to EBITDA used by other issuers.

Sieht gut aus, nur eine Frage der zeit, das der Aktienkurs mitzieht!

Gruss Macos

Purchases under the bid, to be made through the facilities of the TSX only in accordance with the TSX's requirements, may commence on March 3, 2009 and will terminate on March 2, 2010, or on such earlier date as Paladin may complete its purchases pursuant to the notice of intention to make a normal course issuer bid filed with the TSX. For any particular trade, the Corporation will not purchase common shares at a price higher than the price of the immediately preceding trade on the open market by independent parties. The common shares that the Corporation intends to acquire pursuant to the bid will be cancelled.

Paladin also announced that it has renewed an automatic share purchase plan with a broker in order to facilitate repurchases of its common shares under its normal course issuer bid. Under Paladin's automatic share purchase plan, Paladin's broker may repurchase shares under the normal course issuer bid at any time including, without limitation, when Paladin would ordinarily not be permitted to due to regulatory restrictions or self-imposed blackout periods. Purchases will be made by Paladin's broker based upon the parameters prescribed by the TSX and applicable Canadian securities laws and the terms of the parties' written agreement. The automatic share purchase plan has been reviewed by the TSX. The automatic share purchase plan will be renewed effective as of March 3, 2009.

The Board of Directors of Paladin has concluded that the market price of Paladin's common shares, from time to time, may not reflect the inherent value of the Corporation and purchases of common shares pursuant to the bid may represent an appropriate and desirable use of the Corporation's funds.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Corporation's web site at www.paladinlabs.com.

This news release contains forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Corporation considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Corporation and its subsidiaries may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Corporation's Annual Information Form for the year ended December 31, 2007. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Corporation's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com.

Contact:
Samira Sakhia
Paladin Labs Inc.
Chief Financial Officer
514-669-5367
514-344-4675 (FAX)
info@paladin-labs.com
www.paladinlabs.com

Paladin to Present at BioFinance 2009 in Toronto
Wednesday April 22, 2009, 4:04 pm EDT
      Buzz up! Print MONTREAL, CANADA--(Marketwire - April 22, 2009) - Paladin Labs Inc. (TSX:PLB - News), a leading Canadian specialty pharmaceutical company, announced today that Joseph Walewicz, Vice President, Special Projects will present a corporate update at BioFinance 2009 on Wednesday, April 29, 2009 at 11:30 a.m. ET in room Trinity IV of the Toronto Marriott Eaton Centre. A copy of the presentation will be available at www.paladinlabs.com.

About Paladin Labs

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2008. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com

Contact:
Samira Sakhia, Chief Financial Officer
Paladin Labs Inc.
514-669-5367
514-344-4675 (FAX)
info@paladin-labs.com
www.paladinlabs.com

Revenue for the first quarter of 2009 increased 53% or $9.0 million to $25.8 million, compared to $16.8 million in the first quarter of 2008. This increase is due to the acquisition and launch of Dexedrine® and the strong performance from the Company's key promoted products, including TriduralTM, Twinject®, SeasonaleTM, Plan B®, Pennsaid®, Metadol®, Trelstar®, and Testim® which combined increased by 11% in the first quarter of 2009 compared to the corresponding period a year ago.

First quarter 2009 earnings before interest expense, taxes, amortization, and unusual items (EBITDA(1)) increased 103% to $11.0 million, compared to EBITDA(1) of $5.4 million in the first quarter of 2008.

Net income for the quarter was $3.1 million or $0.20 per fully diluted share, compared to net income of $1.5 million or $0.10 per fully diluted share in the first quarter a year ago.

At March 31, 2009, Paladin's cash, cash equivalents and investments in marketable securities totalled $32.5 million. From this strong cash position, Paladin continues to pursue product acquisition and development opportunities.

Product Developments

During the Quarter, Paladin entered into a distribution agreement under which Mission Pharmacal Company granted Paladin the exclusive Canadian rights to market and sell Urocit-K®. Urocit-K® is a slow-release formulation of potassium citrate clinically proven to inhibit the formation of most kidney stones in over 90% of patients. Paladin intends to launch Urocit-K® 540 mg, which is approved for sale in Canada, and submit the 1080 mg formulation for approval in 2009.

In addition, Paladin filed a new drug submission for Trelstar® 22.5 mg (triptorelin pamoate for injectable suspension). Trelstar® 22.5 mg is a 6-month slow release, injectable, luteinizing hormone-releasing hormone (LHRH) agonist indicated for the palliative treatment of advanced prostate cancer. Paladin obtained the Canadian license for Trelstar® from Watson Pharma Inc., a subsidiary of Watson Pharmaceuticals, Inc. (NYSE:WPI - News) in May 2005. Paladin launched Trelstar® 11.25 mg 3 month for the treatment of advanced prostate cancer in August 2006 and launched Trelstar® 3.75 mg 1 month for the treatment of advanced prostate cancer and endometriosis in January 2007.

Corporate Developments

During the quarter Paladin received regulatory approval from the Toronto Stock Exchange to carry out a normal course issuer bid effective March 3, 2009. Paladin has been authorized to purchase up to 811,548 of its common shares in the twelve-month period following the bid's effective date. To date, Paladin has not purchased any common shares under the normal course issuer bid.

(1) EBITDA (earnings before interest, taxes, depreciation and amortization) does not have any standardized meaning under Canadian Generally Accepted Accounting Principles ("GAAP") and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest expense, taxes, amortization, and unusual items; such as write-downs and gains (losses) on intellectual property and investments. EBITDA is calculated and presented consistently from period to period and agrees, on a consolidated basis, with the amount disclosed as "Earnings before under noted items" on the consolidated statement of income. The Company believes EBITDA to be an important measurement that allows it to assess the operating performance of its ongoing business on a consistent basis without the impact of amortization expenses. The Company excludes amortization expenses because their level depends substantially on non-operating factors such as the historical cost of intangible and capital assets. The Company's method for calculating EBITDA may differ from that used by other issuers and, accordingly, this measure may not be comparable to EBITDA used by other issuers.

Conference Call Notice

Paladin will host a conference call to discuss its first quarter results on Thursday, May 7, 2009, at 8:30 a.m. EST. The dial-in number for the conference call is 1-800-589-8577 or 416-915-5765. The call will be audio-cast live and archived for 30 days at www.paladinlabs.com.

About Paladin Labs

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. For more information, please visit the Company's web site at www.paladinlabs.com.

This news release contains forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended December 31, 2008. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Companies' ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at www.sedar.com.

"We are pleased to be partnering with a company like Paladin Labs, a well-regarded commercialization partner, in important pharmaceutical markets," said Dr. Foster, President & CEO of Isotechnika. "We are pleased to be able to secure capital in such a difficult market, while retaining the rights to market voclosporin in the largest, most strategic markets, including the U.S., Europe, Japan and Asia. With this improved capital position, we are better positioned to secure a global commercialization deal for voclosporin."

"This deal provides us with another product with two indications to commercialize outside of Canada. It joins our growing international business, which now includes Impavido® (worldwide), Antizol® (worldwide), Unisom® (Canada, Australia and New Zealand), Pennsaid Plus® and another undisclosed topical pain product (Canada, South Africa, Israel, Central and South America)," added Mr. Goodman.

Over the longer term, Paladin expects that its commercialization expertise and Isotechnika's significant expertise in drug discovery and development, will together identify and acquire through Isotechnika additional late-stage clinical assets. This stands to strengthen Isotechnika's product pipeline and further increase Paladin's development portfolio for Canada and other strategic markets of interest.

In addition, as a result of this transaction Paladin's non-capital losses and investment tax credits available to offset future taxable income has increased by a minimum of $100 million.

The Company will file a preliminary short form prospectus in each of the provinces of Canada for the purpose of qualifying the Common Shares for distribution to the public on or before May 27, 2009 and the offering is scheduled to close on or about June 11, 2009.

The net proceeds from the sale of the Common Shares will be used as follows: (i) to fund the transaction with Isotechnika Inc., (ii) to fund the final payment related to the acquisition of Dexedrine®; (iii) to continue Paladin's strategy of acquiring products with existing sales and to in-license and launch innovative brands; and (iv) for general corporate purposes.

The offering is subject to the receipt of all necessary regulatory and stock exchange approvals.

THE COMMON SHARES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS ABSENT U.S. REGISTRATION OR AN APPLICABLE EXEMPTION FROM U.S. REGISTRATION REQUIREMENTS.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.

weit wird es noch gehen bis die Konsolidierung einsetzt?

keiner weiss es....

Paladin Makes First Step Into Emerging Markets Through Strategic Investment in Pharmaplan
finance.yahoo.com/news/...nto-ccn-2827314072.html?x=0&.v=1

21.10.2010 15:04  
BRIEF-RESEARCH ALERT-Paradigm starts Paladin Labs with buy
Oct 21 (Reuters) - Paladin Labs Inc:

"Paradigm starts Paladin Labs Inc with buy rating; price target of C$34
For a summary of rating and price target changes on S&P 500 companies"...

SOURCE / QUELLE / LINK dieses Ausschnitts:
http://www.finanznachrichten.de/...arts-paladin-labs-with-buy-020.htm

Die Registered Shares o.N. der PALADIN Laboratories Inc. (WKN: 873464; ISIN: CA6959421026; Symbol: PLDLF) befinden sich unmittelbar vor einer JUMP-Position.

Nach meiner Einschätzung werden die START-Buys direct oberhalb derer 20,09 €uros
zu greifen beginnen:

Hallo und schönen guten Morgen Euch allen !

Ich bin ein Frischling im Aktienhandel und suche deshalb Euren Rat .

Ist es ratsam, bei Paladin heute mit €1,13 einzusteigen ?

Wenn ja, bei welcher Börse, ich würde auf Xetra tippen, liege ich richtig?

Freue mich auf Eure Hilfe.